Boehringer Ingelheim, one of the world’s largest pharmaceutical companies, announced a new partnership in China on Monday, and remains upbeat about the market amid strains between Beijing and ...

Targeting PDE4 drives anti-inflammatory and antifibrotic effects, and Boehringer has been working on its own PDE4 inhibitor ...

Dr. Pavol Dobrocky, president and CEO of Boehringer Ingelheim China. [Photo provided to chinadaily.com.cn] Boehringer Ingelheim remains confident about its future business development in China ...

The increased investment in China by Boehringer Ingelheim is part of a larger trend of German businesses expanding operations in the Chinese market, even as some European politicians have been ...

Boehringer Ingelheim’s biopharmaceutical facility in Shanghai, China, meets the conditions to participate in a regulatory reform promoting segmented manufacturing of biological products by the local ...

Boehringer Ingelheim Biopharmaceuticals China, in collaboration with a customer, has successfully passed pre-approval inspections by the European Medicines Agency (EMA) and the US Food and Drug ...

Results presented at this year’s American Thoracic Society International Conference showed that the trials met their primary ...

Boehringer Ingelheim is on track in its target to become ... including Japan and China. A new biomass power plant was also commissioned at its Ingelheim site in Germany to boost on-site renewable ...

Cognizant, as the prime system integrator, began the Boehringer Ingelheim project by codeveloping a program roadmap, agile methodology, and implementation workflow. The overall scope of the ...

Boehringer Ingelheim and Cue Biopharma (NASDAQ:CUE) announced Tuesday a research collaboration and a license agreement to jointly develop and commercialize CUE-501, a treatment developed by CUE ...